Business
Soligenix Announces European Patent Grant for Use of Dusquetide in Oral Mucositis
Peptides for specific use in oral mucositis treatment adds to existing composition of matter claims PRINCETON, N.J., May 16, 2023 /PRNewswire/ -- Soligenix,
About this update from Soligenix, Inc.
[{"type":"text","content":"Peptides for specific use in oral mucositis treatment adds to existing composition of matter claims\nPRINCETON, N.J., May 16, 2023 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the European Patent Office has granted a patent entitled \"Novel Peptides and Analogs for Use in the Treatment of Oral Mucositis\". This granted patent builds on similar intellectual property issued in the United States (U.S.), New Zealand, Japan, Australia and Singapore, as well as many pending patent applications in other jurisdictions worldwide. The granted claims will cover therapeutic uses of dusquetide (active ingredient in SGX942) and related innate defense regulator (IDR) analogs, and adds to composition of matter claims for dusquetide and related analogs that have been issued in the U.S. and worldwide.\n\n \n \n \n \n \n \n\n \n\"Soligenix continues to pursue broad patent coverage for its dusquetide technology, first with composition of matter claims followed by therapeutic use claims in oral mucositis,\" stated Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix. \"Having successfully pursued composition of matter claims in jurisdictions worldwide, we continue to pursue therapeutic use claims like those issued in the U.S. previously and in Europe with this most recent patent. The therapeutic use claims are expected to be generally valid until 2034, which provides significant patent protection and life to dusquetide and our other IDR analogs.\"\nAbout Oral Mucositis\nMucositis is the clinical term for damage done to the mucosa by anticancer therapies. It can occur in any mucosal region, but is most commonly associated with the mouth, followed by the small intestine. It is estimated, based upon review of historic published studies and reports and an interpolation of data on the incidence of mucositis, that mucositis affects approximately 500,000 people in the U.S. per year and occurs in 40% of patients receiving chemotherapy. Mucositis can be severely debilitating and can lead to infection, sepsis, the need for parenteral nutrition and narcotic analgesia. The gastrointestinal damage causes severe diarrhea. These symptoms c...